Given sPIF FAST-Track FDA approval for clinical trial in autoimmune diseases of non-pregnant subjects (clinicaltrials.gov, NCT02239562), prophylactic sPIF treatment in pregnancy can be envisioned. Here, MROH2B is linked to autoimmune disease.